vs
FIRST COMMUNITY CORP（FCCO）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是FIRST COMMUNITY CORP的1.5倍（$35.5M vs $23.2M），FIRST COMMUNITY CORP净利率更高（23.7% vs -304.2%，领先328.0%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 19.1%）
第一社区（南卡罗来纳州）旗下的联合社区银行是一家美国银行，也是美国东南部规模领先的综合性金融机构，目前拥有277亿美元资产，在阿拉巴马州、佛罗里达州、佐治亚州、北卡罗来纳州、南卡罗来纳州和田纳西州共设有200家网点，按资产计算是总部设于南卡罗来纳州的最大银行。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FCCO vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.5倍
$23.2M
净利率更高
FCCO
高出328.0%
-304.2%
两年增速更快
RXRX
近两年复合增速
19.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.2M | $35.5M |
| 净利润 | $5.5M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 23.7% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | 37.6% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCCORXRX
| Q1 26 | $23.2M | — | ||
| Q4 25 | $20.6M | $35.5M | ||
| Q3 25 | $20.5M | $5.2M | ||
| Q2 25 | $19.5M | $19.2M | ||
| Q1 25 | $18.4M | $14.7M | ||
| Q4 24 | $17.5M | $4.5M | ||
| Q3 24 | $17.0M | $26.1M | ||
| Q2 24 | $16.3M | $14.4M |
净利润FCCORXRX
| Q1 26 | $5.5M | — | ||
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $5.2M | $-162.3M | ||
| Q2 25 | $5.2M | $-171.9M | ||
| Q1 25 | $4.0M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $3.9M | $-95.8M | ||
| Q2 24 | $3.3M | $-97.5M |
毛利率FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | -304.8% | ||
| Q3 25 | 32.2% | -3327.6% | ||
| Q2 25 | 34.2% | -916.8% | ||
| Q1 25 | 28.2% | -1297.9% | ||
| Q4 24 | 30.9% | -4042.4% | ||
| Q3 24 | 29.5% | -377.1% | ||
| Q2 24 | 24.7% | -697.4% |
净利率FCCORXRX
| Q1 26 | 23.7% | — | ||
| Q4 25 | — | -304.2% | ||
| Q3 25 | 25.4% | -3135.3% | ||
| Q2 25 | 26.6% | -894.2% | ||
| Q1 25 | 21.8% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 22.7% | -367.5% | ||
| Q2 24 | 20.0% | -676.6% |
每股收益（稀释后）FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | $0.62 | $-0.17 | ||
| Q3 25 | $0.67 | $-0.36 | ||
| Q2 25 | $0.67 | $-0.41 | ||
| Q1 25 | $0.51 | $-0.50 | ||
| Q4 24 | $0.55 | $-0.56 | ||
| Q3 24 | $0.50 | $-0.34 | ||
| Q2 24 | $0.42 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $220.8M | $1.1B |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
总债务FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益FCCORXRX
| Q1 26 | $220.8M | — | ||
| Q4 25 | $167.6M | $1.1B | ||
| Q3 25 | $161.6M | $1.0B | ||
| Q2 25 | $155.5M | $919.1M | ||
| Q1 25 | $150.0M | $933.9M | ||
| Q4 24 | $144.5M | $1.0B | ||
| Q3 24 | $143.3M | $524.6M | ||
| Q2 24 | $136.2M | $584.4M |
总资产FCCORXRX
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.1B | $1.5B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.0B | $1.3B | ||
| Q1 25 | $2.0B | $1.3B | ||
| Q4 24 | $2.0B | $1.4B | ||
| Q3 24 | $1.9B | $726.5M | ||
| Q2 24 | $1.9B | $775.9M |
负债/权益比FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | $18.7M | $-46.1M | ||
| Q3 25 | $9.2M | $-117.4M | ||
| Q2 25 | $-236.0K | $-76.4M | ||
| Q1 25 | $6.4M | $-132.0M | ||
| Q4 24 | $11.6M | $-115.4M | ||
| Q3 24 | $10.8M | $-59.2M | ||
| Q2 24 | $-292.0K | $-82.2M |
自由现金流FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | $17.6M | $-47.3M | ||
| Q3 25 | $9.0M | $-117.6M | ||
| Q2 25 | $-454.0K | $-79.6M | ||
| Q1 25 | $6.2M | $-133.8M | ||
| Q4 24 | $10.5M | $-116.7M | ||
| Q3 24 | $10.6M | $-63.8M | ||
| Q2 24 | $-634.0K | $-83.4M |
自由现金流率FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | 85.3% | -133.1% | ||
| Q3 25 | 44.2% | -2272.5% | ||
| Q2 25 | -2.3% | -413.9% | ||
| Q1 25 | 34.0% | -907.4% | ||
| Q4 24 | 60.3% | -2567.7% | ||
| Q3 24 | 62.5% | -244.6% | ||
| Q2 24 | -3.9% | -578.5% |
资本支出强度FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 3.5% | ||
| Q3 25 | 0.6% | 4.7% | ||
| Q2 25 | 1.1% | 16.4% | ||
| Q1 25 | 1.1% | 12.4% | ||
| Q4 24 | 6.3% | 28.6% | ||
| Q3 24 | 1.1% | 17.5% | ||
| Q2 24 | 2.1% | 8.2% |
现金转化率FCCORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.77× | — | ||
| Q2 25 | -0.05× | — | ||
| Q1 25 | 1.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.80× | — | ||
| Q2 24 | -0.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCCO
| Net Interest Income | $18.4M | 79% |
| Noninterest Income | $4.8M | 21% |
RXRX
暂无分部数据
